Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 14;13:980435. doi: 10.3389/fimmu.2022.980435

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Ji, Zhang, Cheng, Ge, Wang, Fang, Mucker, Chen, Ma, Zhang, Li, Hammond, Baracco, Holbrook, Frieman, Zhang, Wang, Hooper, Zhang and Zhu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Amubarvimab, romlusevimab and amubarvimab+romlusevimab neutralize SARS-CoV-2 VOCs/VOIs in vitro. (A–C) Neutralization potency of amubarvimab, romlusevimab, and their 1:1 combination against SARS-CoV-2 VOCs/VOIs. Data shown represents fold-change in neutralization potencies (IC₅₀) of amubarvimab (A), romlusevimab (B) and amubarvimab+romlusevimab (C) against the past and present circulating VOCs/VOIs compared with the D614G wild-type pseudotyped VLPs. (D–F) In vitro neutralization of wild-type, Beta and Delta authentic live virus with amubarvimab (D), romlusevimab (E), and amubarvimab and romlusevimab together (F). Results are representative of at least two independent experiments.